Conference item icon

Conference item

Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Abstract:

PURPOSE: Glioblastoma is refractory to conventional therapies. The bromodomain and extraterminal domain (BET) proteins are epigenetic readers that selectively bind to acetylated lysine residues on histone tails. These proteins recently emerged as important therapeutic targets in NUT midline carcinoma and several types of hematopoietic cancers. In this study, the therapeutic potential of a novel BET bromodomain inhibitor, JQ1, was assessed in a panel of genetically heterogeneous glioblastoma s...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Oxford Ludwig Institute
Role:
Author
Host title:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
19
Issue:
7
Pages:
1748-1759
Publication date:
2013-04-01
Event location:
United States
DOI:
EISSN:
1557-3265
ISSN:
1078-0432

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP